Study · Animal study (in vivo) · rabbit · 2016
12 resultsKowalski RP, Romanowski EG, Yates KA, Mah FS
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics26 Oct 2015Cited by 69 (Europe PMC)
The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)
Text rights: Publisher copyright. Results still quote short attributed sentences.
12 results from studies that gave the peptide. No result from this study comes from people.
In rabbits, Draize testing classified brilacidin 0.5% as minimally irritating.
In plain wordsIn rabbits, brilacidin eye treatment caused minimal irritation.
rabbitn: not reported in source
Ocular Draize testingSource sentences
In vivo: Draize testing determined BRI 0.5% to be minimally irritating.
In rabbits with abraded corneas, brilacidin did not differ statistically from vancomycin in reducing MRSA.
In plain wordsIn rabbits with damaged corneal surfaces, brilacidin and vancomycin did not differ significantly in reducing MRSA.
rabbitn: not reported in source
MRSA keratitis with abraded corneasSource sentences
For abraded corneas, BRI was not statistically different from VAN for reducing MRSA.
For efficacy testing, both corneas of 24 rabbits were infected with methicillin-resistant S. aureus (MRSA), whereas the corneal epithelium was removed in the left eye.
After 4 h, 21 topical drops over 5 h were administered to 4 groups: BRI 0.5%, vancomycin (VAN) 5%, saline, and no treatment.
In the rabbit keratitis experiment, brilacidin was bactericidal.
In plain wordsIn rabbits with corneal infection, brilacidin killed bacteria.
rabbitn: not reported in source
MRSA keratitisSource sentences
BRI was bactericidal.
For efficacy testing, both corneas of 24 rabbits were infected with methicillin-resistant S. aureus (MRSA), whereas the corneal epithelium was removed in the left eye.
In rabbits with intact corneas, brilacidin reduced fewer CFU than vancomycin.
In plain wordsIn rabbits with intact corneas, brilacidin reduced bacteria less than vancomycin.
rabbitn: not reported in source
MRSA keratitis with intact corneasSource sentences
For intact corneas, VAN reduced more CFU than BRI.
For efficacy testing, both corneas of 24 rabbits were infected with methicillin-resistant S. aureus (MRSA), whereas the corneal epithelium was removed in the left eye.
In rabbits, brilacidin reduced CFU more in abraded than intact corneas.
In plain wordsIn rabbits, brilacidin reduced bacteria more in damaged corneas than in intact corneas.
rabbitn: not reported in source
MRSA keratitisSource sentences
BRI reduced CFU in abraded corneas more than intact corneas suggesting poor corneal penetration.
For efficacy testing, both corneas of 24 rabbits were infected with methicillin-resistant S. aureus (MRSA), whereas the corneal epithelium was removed in the left eye.
In lab tests, S. aureus and S. epidermidis had the lowest brilacidin minimum inhibitory concentrations among tested bacterial groups.
In plain wordsIn lab tests, brilacidin had its lowest inhibitory concentrations against S. aureus and S. epidermidis among tested bacteria.
n: not reported in source
Bacterial isolatesSource sentences
In vitro: Both SA and SE had the lowest minimum inhibitory concentrations among the bacterial groups.
In lab tests, the brilacidin MIC90 for S. pneumonia was 4-fold higher than for S. aureus and S. epidermidis.
In plain wordsIn lab tests, the brilacidin inhibitory concentration for S. pneumonia was higher than for S. aureus and S. epidermidis.
n: not reported in source
Bacterial isolatesSource sentences
The MIC90s to BRI for SP, SV, MS, HI, PA, and SM were 4, 32, 256, 32, 16, and 128-fold higher, respectively, than SA and SE.
In lab tests, the brilacidin MIC90 for S. viridans was 32-fold higher than for S. aureus and S. epidermidis.
In plain wordsIn lab tests, the brilacidin inhibitory concentration for S. viridans was higher than for S. aureus and S. epidermidis.
n: not reported in source
Bacterial isolatesSource sentences
The MIC90s to BRI for SP, SV, MS, HI, PA, and SM were 4, 32, 256, 32, 16, and 128-fold higher, respectively, than SA and SE.
In lab tests, the brilacidin MIC90 for Moraxella was 256-fold higher than for S. aureus and S. epidermidis.
In plain wordsIn lab tests, the brilacidin inhibitory concentration for Moraxella was higher than for S. aureus and S. epidermidis.
n: not reported in source
Bacterial isolatesSource sentences
The MIC90s to BRI for SP, SV, MS, HI, PA, and SM were 4, 32, 256, 32, 16, and 128-fold higher, respectively, than SA and SE.
In lab tests, the brilacidin MIC90 for H. influenzae was 32-fold higher than for S. aureus and S. epidermidis.
In plain wordsIn lab tests, the brilacidin inhibitory concentration for H. influenzae was higher than for S. aureus and S. epidermidis.
n: not reported in source
Bacterial isolatesSource sentences
The MIC90s to BRI for SP, SV, MS, HI, PA, and SM were 4, 32, 256, 32, 16, and 128-fold higher, respectively, than SA and SE.
In lab tests, the brilacidin MIC90 for P. aeruginosa was 16-fold higher than for S. aureus and S. epidermidis.
In plain wordsIn lab tests, the brilacidin inhibitory concentration for P. aeruginosa was higher than for S. aureus and S. epidermidis.
n: not reported in source
Bacterial isolatesSource sentences
The MIC90s to BRI for SP, SV, MS, HI, PA, and SM were 4, 32, 256, 32, 16, and 128-fold higher, respectively, than SA and SE.
In lab tests, the brilacidin MIC90 for S. marcescens was 128-fold higher than for S. aureus and S. epidermidis.
In plain wordsIn lab tests, the brilacidin inhibitory concentration for S. marcescens was higher than for S. aureus and S. epidermidis.
n: not reported in source
Bacterial isolatesSource sentences
The MIC90s to BRI for SP, SV, MS, HI, PA, and SM were 4, 32, 256, 32, 16, and 128-fold higher, respectively, than SA and SE.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.
Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC
Terms as the source lists them.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated